195 related articles for article (PubMed ID: 14998857)
21. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
[TBL] [Abstract][Full Text] [Related]
22. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
Jacobsen E; Freedman A
Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
[TBL] [Abstract][Full Text] [Related]
23. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
[TBL] [Abstract][Full Text] [Related]
24. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S
Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
26. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
27. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
[TBL] [Abstract][Full Text] [Related]
28. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs.
Derigs HG
Cytotherapy; 2000; 2(6):445-53. PubMed ID: 12044225
[TBL] [Abstract][Full Text] [Related]
30. Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase.
Oyan B; Koc Y; Kansu E
Int J Hematol; 2005 Feb; 81(2):155-8. PubMed ID: 15765785
[TBL] [Abstract][Full Text] [Related]
31. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.
Tóthová E; Kafková A; Guman T; Stecová N; Fricová M
Neoplasma; 2003; 50(1):22-5. PubMed ID: 12687274
[TBL] [Abstract][Full Text] [Related]
32. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
Kato H; Taji H; Ogura M; Kagami Y; Oki Y; Tsujimura A; Fuwa N; Kodaira T; Seto M; Yamamoto K; Morishima Y
Clin Lymphoma Myeloma; 2009 Dec; 9(6):443-8. PubMed ID: 19951884
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in autologous stem cell transplantation for follicular lymphoma.
Schmitz N
Anticancer Drugs; 2001 Jun; 12 Suppl 2():S21-4. PubMed ID: 11508933
[TBL] [Abstract][Full Text] [Related]
34. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Corbacioglu S; Eber S; Gungor T; Hummerjohann J; Niggli F
J Pediatr Hematol Oncol; 2003 Apr; 25(4):327-9. PubMed ID: 12679650
[TBL] [Abstract][Full Text] [Related]
35. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
[TBL] [Abstract][Full Text] [Related]
36. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
37. Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL.
Hess G; Flohr T; Derigs HG
Ann Hematol; 2002; 81 Suppl 2():S54-5. PubMed ID: 12611079
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
39. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
[TBL] [Abstract][Full Text] [Related]
40. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Emmanouilides C; Lill M; Telatar M; Rosenfelt F; Grody W; Territo M; Rosen P
Clin Lymphoma; 2002 Sep; 3(2):111-6. PubMed ID: 12435284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]